DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for carcinosarcoma — screening already-approved drugs against its 22-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCarcinosarcoma maps to a 22-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for carcinosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Carcinosarcoma is an aggressive neoplasm that carries a poor prognosis even when diagnosed at an early stage. A 2025 population-based study using the SEER database identified 6,479 patients with carcinosarcoma of the female reproductive tract, with an estimated median cancer-specific survival of 29 months. Among 775 patients with metastatic disease, median cancer-specific survival fell to 9 months. The most common metastatic sites were lung (19.74% of the metastatic cohort) and liver (12.39%), and 41.03% of patients had metastasis to a single site. In multivariable analysis, only tumour size was an independent risk factor for survival in metastatic disease. Surgery and chemotherapy were each associated with significant increases in survival, but radiotherapy was not.
A 2023 cohort of 30 patients with sinonasal carcinosarcoma reported 1-year survival of 79.2% and 5-year survival of 43.3%. Seventy-six percent of these patients received surgery followed by adjuvant radiotherapy. Neither surgical intervention, patient sex, nor patient age independently predicted survival outcomes in that cohort. A 2012 case report and literature review noted that data from prospective or randomised trials are lacking, and that treatment has largely been guided by personal experience and case reviews, with most practitioners recommending aggressive immediate treatment combining surgery, radiation, and variably chemotherapy.
A 2011 review of uterine carcinosarcoma stated that the ideal adjuvant treatment remains unknown, though a number of studies were underway. The 2025 SEER analysis, the largest of the three studies, provides the strongest evidence that surgery and chemotherapy improve survival in metastatic carcinosarcoma, while radiotherapy does not. However, the analysis is retrospective and cannot establish causation. The 2023 sinonasal cohort is small and its results may not generalise to other primary sites.
What is still missing are prospective randomised trials to define optimal adjuvant therapy, reliable biomarkers to stratify patients by risk, and dedicated funding for a disease so rare that most evidence remains retrospective and underpowered.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2011 · 74 citations
Uterine carcinosarcoma
AbstractPURPOSE OF REVIEW: To summarize the clinical characteristics, epidemiology, and treatment of uterine carcinosarcoma. RECENT FINDINGS: Recent studies have suggested that uterine carcinosarcomas are aggressive neoplasms that carry a poor prognosis even when diagnosed at an early stage. Treatment is typically surgical. The ideal adjuvant treatment remains unknown. A number of recent studies have examined the influence of radiation, chemotherapy, and combinations of chemotherapy and radiation for uterine carcinosarcoma. SUMMARY: Carcinosarcoma is an aggressive neoplasm. A number of studies are underway to determine the optimal adjuvant therapy for these tumors.
Journal of Neurological Surgery Part B Skull Base · 2012 · 1 citations
Temporary Brachytherapy Seed Mesh in the Treatment of a Radiation-Induced Sinonasal Carcinosarcoma: A Case Report and Literature Review
AbstractCarcinosarcoma, a true malignant mixed tumor, is a rare and aggressive tumor that has been described infrequently in the literature since 1864 and has yet to be thoroughly studied or understood. Data and evidence obtained from prospective or randomized trials are lacking, and the treatment of this disease has largely been guided by personal experience and case reviews. The majority of experienced practitioners strongly recommend aggressive and immediate treatment combining surgery, different forms of radiation, and, variably, chemotherapy.
Translational Cancer Research · 2025 · 0 citations · open access
Risk factors and treatment strategies for female reproductive system carcinosarcoma with metastasis
AbstractBackground: Carcinosarcomas are rare, aggressive tumors of the female reproductive tract, with limited knowledge regarding their progression, metastasis, risk factors, and treatment, especially in advanced stages. This study aimed to investigate the risk factors and treatment outcomes for metastatic carcinosarcoma using a population-based approach. Methods: A retrospective study based on the Surveillance, Epidemiology, and End Results (SEER) database was conducted in order to identify patients diagnosed with carcinosarcoma and to analyze metastatic trends and patterns. Chi-square tests, Cox regression models, and the Kaplan-Meier method were used to identify risk factors and to assess the outcomes of various treatment strategies. Results: A total of 6,479 patients with carcinosarcoma were identified, with an estimated median cancer-specific survival (CSS) of 29 months. There were 775 patients in the metastatic cohort, with an estimated median CSS of 9 months. The metastasis patterns were mostly one-site metastasis (N=318, 41.03%), and the most common metastases were lung metastasis (N=153, 19.74%), followed by liver metastasis (N=96, 12.39%). A range of variables such as age, race, marital status, stage, grade, and size were found to be risk factors for metastatic carcinosarcoma in the univariable Cox model, but only tumor size was found to be an independent risk factor in the multivariable Cox model. Surgery and chemotherapy were associated with significant increases in survival, but radiotherapy was not. Conclusions: Carcinosarcoma is rare but aggressive and often results in lung and liver metastases. We conclude from our analysis that tumor size is an independent prognostic risk factor in patients with metastases, and we recommend both surgery and chemotherapy for these patients.
World Journal of Otorhinolaryngology - Head and Neck Surgery · 2023 · 0 citations · open access
AbstractThe demographics and outcomes for a cohort of 30 patients with sinonasal carcinosarcoma were described. Seventy-six percent of patients were treated with surgery followed by adjuvant radiotherapy. 1- and 5-year survival from the time of diagnosis were 79.2% and 43.3% respectively. Neither surgical intervention, patient sex, nor patient age independently predicted survival outcomes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
